Fermentation, Biotechnology & Healthcare
Established vs Recombinant Fermentation Industry -
Production Costs and Capacity Requirements by 2005
Recent years have seen considerable change within the fermentation and biotechnology industries due to various factors including:
corporate acquisitions, amalgamations and spin-offs in the pharmaceutical and chemical industry;
commercial introduction of novel biotechnology products;
improved productivity for many fermentation processes requiring lower production capacity;
patent expiry for major healthcare products leading to generic competition, especially from China and India.
This 240-page survey
reviews fermentation capacities by sector [including antibiotics, other health products, organic acids, amino acids, polysaccharides, vitamins and biotechnology products for 2000
profiles every company engaged in fermentation and biotechnology, listing sales of their fermentation and biotechnology products, location of plants, new plants and novel biotech products
analyses production costs of 15 fermentation products [including streptokinase, insulin, interferon, -amylase, lysine, and citric acid]
discusses the future outlook of fermentation and biotechnology by 2005.
This survey has been used by major fermentation and biotechnology corporations in the pharmaceutical and chemical industries for strategic corporate planning to determine management strategy by 2005 with regard to investment in new fermentation and biotechnology plant or alternatively resorting to tolling facilities.
The Antibiotics Industry - Current Status & Outlook
Within the past decade the antibiotics industry has undergone radical changes attributed to various factors, including:
- Chinese and Indian producers selling bulk b-lactams and tetracyclines at extremely low prices.
- mergers and amalgamations of Western pharmaceutical companies into larger groups and a trend to out-source antibiotics production;
- increasing resistance of infectious bacteria against broad and narrow spectrum antibiotics;
Our latest survey of the Antibiotics Industry has the following objectives:
assessing the output of specific categories of antibiotics incl. ß-lactams, macrolides, tetracyclines];
- profiling producers of antibiotics in Europe, U.S., Japan, Korea, India and China, their output of antibiotics, markets and capacities;
- determining production cost of various antibiotics [incl. penicillin, cephalosporin, erythromycin], intermediates and semi-synthetic derivatives;
- reviewing the outlook for antibiotics by 2005.
Chiral Compounds from Biotechnology -
Production Costs, Economics and Technology
Chirality is recognized as the key to the efficacy of many biopharmaceutical, products in use today. For example, antibiotics, alkaloids and steroids - isolated from natural sources or by fermentation - and their semi-synthetic derivatives are optically pure, containing a few or many asymmetric carbon atoms per molecule. Their racemic counterparts produced by chemical synthesis may be totally inactive or exhibit reduced activity.
The survey determines the status of chiral products in the biopharmaceutical area with particular reference to the production costs and economics of biotechnological process routes including:
- fermentation
- microbial transformation
- soluble enzyme conversion
- immobilized biocatalysis - with enzymes
- immobilized biocatalysis - with biomass.
This 200-page report serves as a valuable aid to assist management in biopharmaceuticals concerning process selection and economics.
The Steroid Industry Opportunities for Bulk & Generics
A comprehensive review of the steroid industry with emphasis on raw materials, [soya, sterols, diosgenin] intermediates [ADD, 16 ] and derivatives, including:.
synthesis of steroid intermediates and derivatives
steroid derivatives for various therapeutic indications
- production cost of intermediates and derivatives
steroid companies and sales
- prices, feedstock utilisation, output and market.
This survey has been used in planning corporate strategy.
Toll Fermentation - Opportunities for U.S. & European Companies
In recent years many fermentation companies have become involved in toll manufacture of antibiotics, enzymes, agricultural products, organic acids, amino acids, vitamins and other food/feed additives. In this survey we have estimated the tolling capacity of European and U.S. companies and what proportion of total fermentation capacity this represents. Various European and U.S. companies involved in tolling are profiled and their capacities given. The fixed and variable costs of toll fermentation plants are estimated. Selling prices of products made in small and large-capacity plants are analysed.
Recombinant Insulin - Current Status and Outlook
Human insulin derived from E. coli or yeast has virtually replaced insulin from bovine and procine pancreas. In this survey the production process for recombinant insulin from E. coli and yeast is reviewed and the manufacturing cost estimated:
- using E. coli & yeast strains
- manufacturing cost for insulin precursor
- manufacturing cost for bioactivation and purification
The insulin market worldwide is assessed, producers listed and the future outlook determined.
Carbohydrate Feedstocks for the Fermentation Industry
A detailed survey analysing the carbohydrate feedstocks [glucose, starch, molasses, sugar] used in the production of ethanol, yeast, organic acids, amino acids, antibiotics.
- feedstock requirements for fermentation processes
- feedstock production, prices and trends
- total usage of feedstock in fermentation industry
- feedstock cost as percentage of product price
Nitrogen Media in Fermentation
A detailed survey dealing with the use of nitrogen media in fermentation and biotechnology including the following sections:
Nitrogen media, both inorganic and organic, used in industrial fermentation processes, their composition, prices and nitrogen cost per ton medium;
Nitrogen [organic and inorganic] media used in various industrial fermentation processes including antibiotics, organic acids, enzymes, amino acids, polysaccharides, vitamins, starter cultures and yeast are reviewed and the consumption is estimated;
Summary including total consumption of organic and inorganic N media used in fermentation processes worldwide and opportunities for introduction of novel nitrogen- containing media especially in biotechnology processes based on recombinant microorganisms.